CAMZYOS® ▼ (mavacamten)
PATIENT CARD

Patient instructions: Carry this card with you **at all times**. Tell any healthcare professional who sees you that you are taking CAMZYOS.

CAMZYOS is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Refer to the Patient Guide and package leaflet for more information, or contact AM Mangion Ltd – 00 356 23976000

Safety information for patients of childbearing potential:

- CAMZYOS may cause harm to an unborn baby if used during pregnancy
- CAMZYOS must not be taken if you are pregnant or are of childbearing potential and are not using an effective method of contraception
- If you are able to get pregnant, you must use an effective method of contraception throughout treatment and for 6 months after your last dose
- Talk to your doctor if you are considering becoming pregnant
- If you suspect that you may be pregnant or are pregnant, you must inform your prescriber or doctor **immediately**

Safety information for all patients:

- Tell your prescriber or doctor or seek other medical attention **immediately** if you experience new or worsening symptoms of heart failure, including shortness of breath, chest pain, fatigue, a racing heart (palpitations), or leg swelling
- Tell your prescriber or doctor of any new or existing medical conditions
- Tell your prescriber, doctor or pharmacist about your treatment with CAMZYOS before starting any new medicines (including prescription and those available over-the-counter) or herbal supplements, since some of them can increase the amount of CAMZYOS in your body and make it more likely for you to get side effects (some of which may be severe). Do not stop taking or change the dose of any medicine or herbal supplement that you are already taking without talking to your doctor or pharmacist first, as other medicines can affect the way CAMZYOS works

Date of Health Authority Approval: 18March2024
Local Approval Number: **3500-MT-2400002 – v1**

Please complete this section or ask your prescriber of CAMZYOS to complete it.

Patient's name	
Name of prescriber	
Office phone number	
After-hours phone number	
Hospital name (if applicable)	

▼CAMZYOS is subject to additional monitoring. This will allow for the quick identification of new safety information. You can help by reporting any side effects that you may experience.

The safe use of CAMZYOS is of paramount importance. As part of our ongoing safety monitoring, Bristol Myers Squibb wishes to be informed of adverse events that have occurred during use of CAMZYOS. Please report any adverse events and pregnancies to: AM Mangion Ltd on Tel No 00356 23976333 and email pv@ammangion.

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported

using the Medicines Authority ADR reporting form available online at http://www.medicinesauthority.gov.mt/adrportal and sent to the Pharmacovigilance Section

at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta

Life Sciences Park, San Ġwann SĠN or sent by email to:

postlicensing.medicinesauthority@gov.mt

Date of Health Authority Approval: 18March2024
Local Approval Number: **3500-MT-2400002 – v1**

Date of Health Authority Approval: 18March2024
Local Approval Number: **3500-MT-2400002 – v1**